Group Based Opioid Treatment
Recorded On: 04/21/2021
ORN Webinar Series: This webinar will introduce a group-based format to deliver opioid use disorder (OUD) treatment incorporating medications and psychosocial programming. The number of people in need of OUD treatment continues to woefully outpace the availability of treatment providers. Providing treatment with multiple patients in a group-based setting is a strategy that can markedly expand access. Other benefits include enhancing patient recovery networks, improving provider satisfaction and financial viability.
Goals & Objectives:
- Identify the advantages of implementing a shared medical appointment for prescribing medication for OUD and incorporating group therapy.
- Recognize the impact the COVID pandemic has had on substance use disorders.
- Understand the benefits and challenges of utilizing telehealth to deliver group treatment.
There is a profound need to expand evidence based treatment for OUD in a manner that is efficient and effective. Providing a group based modality is an innovative way to meet this need. Doing so requires a sound understanding of the processes and particulars of group treatment rather than individual treatment. Furthermore, the COVID epidemic has created many challenges for people with substance use disorders and provision of treatment. An understanding of the unique dynamics of telemedicine delivery in a group format is a way to meet these challenges
This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.
Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
James H. Berry, DO
James H. Berry, DO, is an addiction psychiatrist and Chair of the Department of Behavioral Medicine and Psychiatry at West Virginia University School of Medicine. He and his colleagues at WVU have developed innovative community based treatment models in response to the addiction crisis in Appalachia and are actively engaged in novel neuromodulation research related to substance use disorders through WVU’s Rockefeller Neuroscience Institute.
Julie Kmiec, DO, FAOAAM (Moderator)
Julie Kmiec, DO, FAOAAM graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and the Narcotic Addiction Treatment Program Buprenorphine Clinic at WPIC. Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and medication assisted treatment of addictions. President of the American Osteopathic Academy of Addiction Medicine, 2019 & 2020.
Planner & Moderator for this webinar.